Edition:
United States

UCB SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

59.54EUR
2 Dec 2016
Change (% chg)

€-0.06 (-0.10%)
Prev Close
€59.60
Open
€59.40
Day's High
€59.84
Day's Low
€58.87
Volume
277,527
Avg. Vol
281,285
52-wk High
€86.05
52-wk Low
€57.94

Select another date:

Tue, Nov 15 2016

BRIEF-UCB says head-to-head study of Cimzia and Humira did not meet primary endpoints

* The Lancet publishes first head-to-head study of Cimzia (certolizumab pegol) and Humira (adalimumab) in bio-naïve rheumatoid arthritis patients

BRIEF-UCB gives results from phase 3 bridge study

* Results from phase 3 Bridge study showed romosozumab significantly increased bone mineral density in men with osteoporosis

BRIEF-UCB's anti-epileptic drug VIMPAT receives positive opinion by EU CHMP

* UCB's anti-epileptic drug VIMPAT (lacosamide) receives positive opinion by EU CHMP as monotherapy for patients with partial-onset seizures Source text: http://bit.ly/2fIeuV8 Further company coverage: (Gdynia Newsroom)

Belgium's UCB guides for upper end of 2016 forecast range

BRUSSELS, Oct 25 Belgian pharma group UCB on Tuesday said its 2016 results should come in at the upper end of its guidance range, as its main products sold strongly in the first nine months of the year.

BRIEF-UCB Q3 revenue up 7 pct, 2016 guidance confirmed

* Reports 9 month revenue of 3.08 billion euros ($3.35 billion) versus 2.86 billion euros year ago

BRIEF-UCB CIMZIA Phase 3 trial meets co-primary efficacy endpoints

* CIMZIA (certolizumab pegol) Phase 3 trial meets co-primary efficacy endpoints in patients with moderate-to-severe chronic plaque psoriasis

BRIEF-Amgen and UCB say FDA accepts biologics license application for romosozumab

* Amgen and UCB announce FDA acceptance of biologics license application for romosozumab

BRIEF-UCB receives positive EU CHMP opinion for Cimzia

* Receives positive EU CHMP opinion for Cimzia (certolizumab pegol) autoclicks Prefilled Pen Source text: http://bit.ly/2cWGynH Further company coverage: (Gdynia Newsroom)

European stocks touch 7-week highs, supported by pharma shares

LONDON, Aug 15 European stocks climbed to their highest level in seven weeks on Monday, supported by firmer healthcare stocks after Belgian pharmaceuticals group UCB won a favourable U.S. court ruling.

European stocks lifted to 7-week highs by pharma shares

LONDON, Aug 15 European stocks climbed to their highest level in seven weeks on Monday, lifted by firmer healthcare stocks after Belgian pharmaceuticals group UCB won a favourable U.S. court ruling.

Select another date: